Amylyx Pharmaceuticals (AMLX): Guggenheim is excited about the pipeline and outlook!
Reading Time: 2 minutes
Amylyx Pharmaceuticals Inc. (AMLX) has evolved into a company that is worth a closer look for investors following its recent realignment of its development strategy. A central component of the Amylyx pipeline is Avexitide, a potential "First-in-Class" GLP-1 receptor antagonist. This molecule is currently being investigated in the pivotal phase-3 LUCIDITY trial for the treatment of post-bariatric hypoglycemia (PBH). PBH is a rare but serious complication that can occur after bariatric surgeries. Recruitment for the LUCIDITY study is expected to be...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
